Patient Reported Experiences and Delays During the Diagnostic Pathway for Pulmonary Fibrosis: A Multinational European Survey. by van der Sar, Iris G et al.
ORIGINAL RESEARCH
published: 04 August 2021
doi: 10.3389/fmed.2021.711194
Frontiers in Medicine | www.frontiersin.org 1 August 2021 | Volume 8 | Article 711194
Edited by:
Mehdi Mirsaeidi,
University of Miami, United States
Reviewed by:
Alyson W. Wong,







†These authors share first authorship
Specialty section:
This article was submitted to
Pulmonary Medicine,
a section of the journal
Frontiers in Medicine
Received: 18 May 2021
Accepted: 12 July 2021
Published: 04 August 2021
Citation:
van der Sar IG, Jones S, Clarke DL,
Bonella F, Fourrier JM,
Lewandowska K, Bermudo G,
Simidchiev A, Strambu IR,
Wijsenbeek MS and Parfrey H (2021)
Patient Reported Experiences and
Delays During the Diagnostic Pathway




Patient Reported Experiences and
Delays During the Diagnostic
Pathway for Pulmonary Fibrosis: A
Multinational European Survey
Iris G. van der Sar 1†, Steve Jones 2†, Deborah L. Clarke 3, Francesco Bonella 4,
Jean Michel Fourrier 5, Katarzyna Lewandowska 6, Guadalupe Bermudo 7,
Alexander Simidchiev 8, Irina R. Strambu 9, Marlies S. Wijsenbeek 1 and Helen Parfrey 10*
1 Erasmus Medical Center, Rotterdam, Netherlands, 2 Action for Pulmonary Fibrosis, Lichfield, United Kingdom, 3Galapagos
NV, Mechelen, Belgium, 4 Ruhrlandklinik, University of Duisburg-Essen, Essen, Germany, 5 Association Pierre Enjalran Fibrose
Pulmonaire Idiopathique, Meyzieu, France, 6Department of Pulmonary Diseases, National Research Institute of Tuberculosis
and Lung Diseases, Warsaw, Poland, 7Hospital Universitari de Bellvitge, Barcelona, Spain, 8Department of Functional
Diagnostics, Medical Institute MVR, Sofia, Bulgaria, 9Carol Davila University of Medicine and Pharmacy, Bucharest, Romania,
10 Royal Papworth Hospital, Cambridge, United Kingdom
Introduction: Pulmonary fibrosis includes a spectrum of diseases and is incurable.
There is a variation in disease course, but it is often progressive leading to increased
breathlessness, impaired quality of life, and decreased life expectancy. Detection of
pulmonary fibrosis is challenging, which contributes to considerable delays in diagnosis
and treatment. More knowledge about the diagnostic journey from patients’ perspective
is needed to improve the diagnostic pathway. The aims of this study were to evaluate
the time to diagnosis of pulmonary fibrosis, identify potential reasons for delays, and
document patients emotions.
Methods: Members of European patient organisations, with a self-reported diagnosis
of pulmonary fibrosis, were invited to participate in an online survey. The survey assessed
the diagnostic pathway retrospectively, focusing on four stages: (1) time from initial
symptoms to first appointment in primary care; (2) time to hospital referral; (3) time to first
hospital appointment; (4) time to final diagnosis. It comprised open-ended and closed
questions focusing on time to diagnosis, factors contributing to delays, diagnostic tests,
patient emotions, and information provision.
Results: Two hundred and seventy three participants (214 idiopathic pulmonary fibrosis,
28 sarcoidosis, 31 other) from 13 countries responded. Forty percent of individuals took
≥1 year to receive a final diagnosis. Greatest delays were reported in stage 1, with
only 50.2% making an appointment within 3 months. For stage 2, 73.3% reported a
hospital referral within three primary care visits. However, 9.9% reported six or more
visits. After referral, 76.9% of patients were assessed by a specialist within 3 months
(stage 3) and 62.6% received a final diagnosis within 3 months of their first hospital
visit (stage 4). Emotions during the journey were overall negative. A major need for
more information and support during and after the diagnostic process was identified.
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Conclusion: The time to diagnose pulmonary fibrosis varies widely across Europe.
Delays occur at each stage of the diagnostic pathway. Raising awareness about
pulmonary fibrosis amongst the general population and healthcare workers is essential
to shorten the time to diagnosis. Furthermore, there remains a need to provide patients
with sufficient information and support at all stages of their diagnostic journey.
Keywords: pulmonary fibrosis, delayed diagnosis, diagnostic journey, survey, patient reported outcomes
INTRODUCTION
Interstitial lung disease (ILD) describes a relatively uncommon
group of diseases characterised by inflammation and fibrosis
of the lung interstitium. Pulmonary fibrosis is a chronic, and
often progressive condition. There is, however, considerable
variation amongst patients in terms of aetiology, treatment
strategies, and disease course (1). Amongst all types of
pulmonary fibrosis, idiopathic pulmonary fibrosis (IPF) is the
most prevalent and accounts for about two-thirds of cases.
It has the worst prognosis due to rapid disease progression
with a mean survival of 4 years from diagnosis without anti-
fibrotic therapy (2). Other types of progressive pulmonary
fibrosis include chronic hypersensitivity pneumonitis, auto-
immune disease related ILD, and occupational diseases such as
asbestosis (1). Epidemiological data for all types of pulmonary
fibrosis are limited as most registries and studies have focused
on IPF or progressive phenotypes only (3). The reported
prevalence (per 100,000 persons) of the ILDs that most often
result in pulmonary fibrosis is 30.2 for sarcoidosis, 12.1
for ILD related to a connective tissue disease and 8.2 for
IPF. Overall, the proportion of ILD patients who develop
pulmonary fibrosis varies from 13 to 100% per individual
disease (1).
The diagnostic journey usually starts with patients presenting
to their primary care physicians with initial symptoms of cough
or mild dyspnoea. These non-specific symptoms, combined with
the heterogeneity, and rarity of pulmonary fibrosis, as well as
requirement for multiple diagnostic investigations, results in a
prolonged time to diagnosis with potential delays related to
patient factors and healthcare systems (4). Reported time to
diagnosis from the onset of initial symptoms varies in different
studies but may be up to a median of 2.1 years (IQR 0.9–
5.0) (5). Longer time to diagnosis is associated with worse
outcomes in IPF (6, 7), causes delayed treatment, leads to
more extensive fibrosis (8) and affects patients’ well-being.
Therefore, it is important to get better insights into patients’
experiences during the diagnostic journey to identify reasons
for potential delays. Understanding patients’ experiences will
also help healthcare workers guide and support patients during
their diagnosis journey. However, to date, only a few studies
have explored the reasons for diagnostic delays using data
reported by pulmonary fibrosis patients (9–13). Most analyses
are based on retrospective data obtained from healthcare
records (5, 7, 8, 14–18).
In this paper, we present data obtained from a multinational
patient survey regarding time to diagnosis and potential causes
for diagnostic delays, together with patient experiences on the
pathway to diagnosis. Based upon these findings, we provide
general recommendations to improve the diagnostic process.
METHODS
Survey Design and Distribution
A survey was designed to collect quantitative and qualitative
data from patients diagnosed with pulmonary fibrosis across
Europe. This survey was developed based upon amarket research
survey on the IPF patient journey (unpublished data) carried
out using a mixture of in-depth telephone interviews with 28
patients and 30 pulmonologists, and online interviews with 315
pulmonologists spanning USA, France, Germany, Italy, Spain,
United Kingdom, Australia, Brazil, Canada, and Japan. The
patient survey was developed jointly between Galapagos and
two patient organisations: Action for Pulmonary Fibrosis (APF,
based in the United Kingdom) and the European Idiopathic
Pulmonary Fibrosis and Related Disorders Federation (EU-
IPFF). Insights from this patient journey research resulted
in a questionnaire incorporating both closed and open-ended
questions, which focused on the following four stages of the
patient journey to identify key points in the delay to diagnosis.
The first stage was the time from first onset of symptoms
at home, before seeking medical attention in a primary care
setting; the second the amount of visits in primary care
before being referred to a hospital specialist; the third the
time taken to be seen in a hospital by a specialist; and
the last the time taken to receive a diagnosis (Figure 1A).
The survey also gathered data on the overall time from first
onset of symptoms to diagnosis and information provided
by healthcare workers. Patients were also asked about their
feelings throughout the diagnostic journey and to provide
advice for patients navigating this journey in the future. No
personalised data were collected and all data were anonymised.
The questionnaire was designed in English and translated into
seven languages (Bulgarian, Dutch, French, German, Hungarian,
Italian, and Spanish) by a certified translation agency. It was
created using the Typeform R© platform. Patients were invited to
complete the questionnaire by an e-mail containing a link to the
platform. The complete survey in English can be found in the
Supplementary Material 1.
The survey was disseminated by the EU-IPFF through its
member patient organisations in Europe; these organisations
distributed the survey to members and other patients through
email and social media. Patients with a self-reported diagnosis
of pulmonary fibrosis, and who had an email address and
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FIGURE 1 | Diagnostic pathway and time to diagnosis. (A) Schematic overview of the diagnostic pathway for pulmonary fibrosis, including stages and topics
assessed in the survey. (B) Patient reported time per stage. (C) Patient reported overall time to diagnosis. PF, pulmonary fibrosis.
internet access were eligible to participate. The survey
was sent out on 7th June 2020 with a reminder after 2
weeks. It closed on 1st July 2020. Ethical review was not
required for this online questionnaire. Patients agreed with
the use of their responses for further analysis without
collection of personal data and were informed that all data
was anonymised.
Data Analysis
Responses in languages other than English were translated
into English by a certified translation agency. Open-
ended questions were assessed qualitatively and coded or
categorised for interpretation. Data were uploaded and
calculations were performed in Excel (Microsoft, Redmond,
WA, USA). R version 4.0.3 for Mac OS X GUI (PBC,
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Boston, MA, USA) was used for creating a word cloud.
All responses were included in the analysis, except for
blank responses.
Literature Search
In addition to the survey, a literature search on diagnostic delays
in ILD, with a focus on pulmonary fibrosis, was conducted in
order to provide a complete overview of the available evidence
from patient surveys, physician surveys, andmedical file analysis.
The systematic literature search was performed in Embase,
Medline, Web of science, Cochrane, and Google scholar
databases. The following search terms were used: diagnostic
delay, time to diagnosis, interstitial lung disease (including
sarcoidosis, vasculitis, interstitial pneumonia). Full search and
outcome can be found in the Supplementary Material 2. Animal
studies, paediatric subjects and articles in languages other than
English were excluded. The reference list was screened for
relevance by title and abstract. Letters to the editor, abstracts,
posters, and articles without available full text were excluded.
RESULTS
Respondent Characteristics
Two hundred and seventy three patients from thirteen different
countries responded. The largest group of respondents were
IPF patients (n = 214, 78.4%), followed by sarcoidosis (n
= 28, 10.3%). Other types of pulmonary fibrosis diagnoses
accounted for 31 respondents (11.4%) and included patients
with autoimmune related disorders, chronic hypersensitivity
pneumonitis, and other conditions. The majority of respondents
received a diagnosis of pulmonary fibrosis in Spain (21.6%),
Belgium (20.1%), United Kingdom (18.3%), Italy (17.2%), or
Germany (10.6%). A smaller number of respondents were
diagnosed in the Netherlands (3.3%), Bulgaria (2.6%), France
(1.8%), Poland (1.8%), Austria (1.5%), Ireland (0.4%), Norway
0.4%), and Romania (0.4%). Shortness of breath, dry cough,
and tiredness were the most common initial symptoms in all
diagnosis groups (Figure 2A).
The total time from initial symptom onset to a final
diagnosis of pulmonary fibrosis, varied greatly amongst patients
(Figure 1C). Overall, nearly 30% received a diagnosis within
3 months, with 31.3% patients with IPF receiving a diagnosis
within 3 months, compared to 14.3% for sarcoidosis and 19.4%
for other types of pulmonary fibrosis. Moreover, 40.2% of all
patients had to wait a year or more to be diagnosed, with the
largest difference between the proportion of patient with IPF
(36.4%) and other types of pulmonary fibrosis (58.1%).
Stages of the Diagnostic Process
Stage 1: From Initial Symptom Onset to First Primary
Care Assessment
More than half of respondents made a first appointment with
a primary care physician within 3 months of symptom onset
(52.0%), but nearly 30% waited more than 6 months (Figure 1B,
stage 1). A number of patients responded that they did not delay
visiting their doctor (26.7%).
Of all patients with a delay in stage 1 of 6 months or less
(n = 177), 65.0% reported a total time to diagnosis of 1 year
or less. Where patients with a delay of more than 6 months
(n = 72) in this stage, only 34.7% reported being diagnosed
within a year.
There were a variety of reasons for delays (Figure 2B).
In a large number of cases, patients delayed seeking medical
advice because they were not concerned about their symptoms.
Patients believed symptoms were related to other causes (e.g.,
cold, smoking, stress; 35.2%), related to age (25.6%), or due
to another established disease (5.1%). The main reasons that
triggered patients to make an appointment with their primary
care physician were worries about their symptoms, including
shortness of breath (45.1%), cough (31.9%), and fatigue (20.9%)
(Figure 2C). For 18.7% of patients, it was the impact of symptoms
on their daily activities, especially on physical activity (e.g.,
sports, climbing stairs, walking, household, gardening) andwork-
related activities that led them to consult their primary care
physician. In addition, some patients were prompted to make an
appointment following the suggestion from family members or
friends (22.7%), or another physician (7%).
Stage 2: From Start of Primary Care Assessment to
Referral to Pulmonologist
At the first primary care appointment, a variety of actions were
taken by the treating physicians. Almost half of all patients
were referred to a pulmonologist (Figure 3). Other reported
physician’s actions included additional tests (19.0%), treatment
for another disease (16.5%), and referral to other specialists
rather than a pulmonologist (10.3%). Overall, the majority
(73.3%) of patients were referred to a pulmonologist within three
primary care visits, but for 9.9% of patients it took six or more
appointments (Figure 1B, stage 2).
Comparing the different diagnosis groups, 43.2% of IPF
patients were referred to a pulmonologist after one primary care
visit. This was lower for those with sarcoidosis (28.6%) and
other types of pulmonary fibrosis (25.8%). Furthermore, 39.3% of
sarcoidosis patients were referred after six or more primary care
visits, compared to 6.6% of IPF and 6.7% of other fibrosis types
in this cohort.
Stage 3: From Referral to First Hospital Appointment
Once patients were referred to a pulmonary specialist, 76.9%
of all patients had their first visit within 3 months (Figure 1B,
stage 3). This was lower for the subgroup of sarcoidosis patients
(50.0%) compared to IPF (79.9%), and other types of pulmonary
fibrosis (80.6%). Few IPF patients (2.3%) had a delay of more
than a year from referral to first hospital appointment, in contrast
to almost a third of the sarcoidosis patients (32.1%). All patients
with other types of pulmonary fibrosis were assessed within a year
of the referral.
Stage 4: From First Hospital Appointment to
Diagnosis Pulmonary Fibrosis
The 273 respondents underwent a total of 1,232 diagnostic tests
in the hospital (Table 1). Themajority of patients reported having
performed spirometry (n = 246), blood tests (n = 222) and
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FIGURE 2 | Patient symptoms and motives in stage 1. (A) Number of patients (n =) reporting a specific symptom at onset. Bars are divided into diagnosis groups
(total responses n = 532). (B) Reason to delay the initial primary care appointment (n = 277). (C) Reason to schedule the initial primary care appointment (n = 463).
Percentages do not add up to 100% as more than one response was allowed. IPF, idiopathic pulmonary fibrosis.
chest imaging (X-ray n = 209; CT scan n = 201) without
large differences in proportions between the diagnosis subgroups.
Other tests reported included assessment of 6-min walk test
(n = 149), lung biopsy (n = 125), and bronchoaveolar lavage
(n = 74). Lung biopsy was more frequently reported by
sarcoidosis patients compared to the other subgroups.
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FIGURE 3 | Action of physician at first visit primary care. Percentages do not add up to 100% as more than one response was allowed. Total responses n = 306.
COPD, chronic obstructive pulmonary disease; GP, general practitioner.
TABLE 1 | Performed tests in hospital before diagnosis.
IPF (n = 214) Sarcoidosis (n = 28) Other type (n = 31)
Tests n = % of patients in subgroup n = % of patients in subgroup n = % of patients in subgroup
Spirometry 194 90.7% 24 85.7% 28 90.3%
Blood tests 168 78.5% 26 92.9% 28 90.3%
Chest X-ray 161 75.2% 22 78.6% 26 83.9%
CT scan 156 72.9% 19 67.9% 26 83.9%
6-min walk test 120 56.1% 10 35.7% 19 61.3%
Lung biopsy 93 43.5% 19 67.9% 13 41.9%
Bronchoaveolar lavage 49 22.9% 11 39.3% 14 45.2%
Other/Don’t know 5 2.3% 1 3.6% - -
Tests per patient (mean) 4.4 4.7 5.0
Number of patients (n =) reporting a specific diagnostic test. Percentages do not add up to 100% as more than one response was allowed. CT, Computed tomography; IPF, idiopathic
pulmonary fibrosis.
Although the final diagnosis was made within 3 months of
the first hospital appointment for 62.6% of the 273 patients
(Figure 1B, stage 4), 21.6% took between 3 months and 1 year,
and 13.2% took over 1 year; 2.6% did not know how long this
took. Small differences were found between the proportion of
patients in each diagnosis group who were diagnosed within
3 months (IPF 64.5%, sarcoidosis 50.0%, and other pulmonary
fibrosis types 61.3%) and more than 1 year after the first
hospital appointment (IPF 11.2%, sarcoidosis 21.4%, and other
pulmonary fibrosis types 19.4%).
Experiences and Recommendations
Information Provision
We assessed the patient perceptions on the information provided
at the different stages in the diagnostic pathway. During
assessment at the hospital (stage 4), 13.6% of patients reported
not knowing why certain diagnostic tests were being performed.
Almost a quarter (23.6%) of all patients felt they received
insufficient information. At diagnosis, most patients (75.6%)
received an explanation about their diagnosis from a physician
and/or specialist nurse during a consultation. However, only
6.0% percent of patients received educational materials and 6.0%
received information related to support groups. A small number
(3.0%) reported not having received any information at the time
of diagnosis. In response to an open-ended question, patients
reported that the discussion with their doctor or nurse was
particularly valuable, as well as ongoing follow up appointments
at the hospital and contact details to enable them to ask questions
or reach out if they were feeling unwell.
The patients stated that they would have benefitted from
more information during the diagnostic process, not only after
the diagnosis was established. They would have welcomed
more information before, at and after diagnosis on the
following topics: differential diagnosis, diagnostic tests, available
pharmacological, and non-pharmacological therapies, disease
course, and prognosis. Respondents would have also liked more
information on living with pulmonary fibrosis day-to-day, future
perspectives, access to a psychologist, and information on peer
support groups for patients and carers.
Emotional Experiences
Patients’ perceptions and experiences were retrospectively
assessed at different time points during their diagnostic journey.
When describing their feelings after the onset of symptoms
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FIGURE 4 | Reported feelings during stage 3. Words grouped after coding,
ones with minimum frequency of 2 are included in figure (n = 28). Full list (n =
62) can be found in Supplementary Material 3.
before their first doctor’s visit (n = 179 responses), 65.4% of
the respondents experienced negative emotions, 5.6% positive
emotions, and the remainder (29.1%) were neutral. When
asked to describe feelings after referral to the hospital (n =
240 responses), 74.6% of the responding patients experienced
negative emotions at that time (16.7% neutral, 8.8% positive)
(Figure 4).
Recommendations to Patients
Overall, the advice and tips offered by patients to those
undiagnosed or living with pulmonary fibrosis were: seeking
help early when you experience symptoms, pushing for a
speedier diagnosis, seeking as much information as possible
from healthcare professionals at all stages, taking regular
exercise, joining pulmonary rehabilitation classes to assist
with breathlessness, joining patient support groups, remaining
positive, pacing themselves, and making the most of their time.
General tips for fellow patients regarding mental well-being
contained phrases such as: stay calm, stay positive, no stress, don’t
despair, don’t give up, focus on the present, and don’t get agitated,
frustrated or anxious.
Recommendations to Healthcare
Advices to healthcare workers included performing tests earlier,
providing more information and lifestyle advice, gaining more
knowledge about pulmonary fibrosis, improving communication
between healthcare workers, structuring the diagnostic process
better, and earlier start of pharmacological and palliative
treatment. More recommendations are listed as quotes in
Supplementary Material 4.
DISCUSSION
The purpose of this survey was to document the time taken to
diagnosis and to identify potential causes of delays at different
stages of the diagnostic pathway for pulmonary fibrosis patients
in Europe. The second aim was to describe patients’ experiences
during this journey.
We found that the time to diagnosis varies widely. Only 30% of
patients were diagnosed with pulmonary fibrosis within 3months
of symptom onset, while for over 40% of patients it took more
than 1 year to be diagnosed. Other studies observed a median
time from onset of first symptoms to diagnosis of 7 months
(range 0–252) based on a patient survey (9) and 2.1 years (IQR
0.9–5.0) from a retrospective cohort study (5). In 2020, a group
of ILD specialists reported a mean time from symptom onset to
pulmonary fibrosis diagnosis of 2.3 years (Q1–Q3: 2–3) (19). The
proportion of patients in our cohort who took more than a year
to be diagnosed is smaller than that reported by other studies of
pulmonary fibrosis patients (9, 11). Moreover, in a study of IPF
patients, the median time to diagnosis was 13.6 months (range
5.9–39.5; max. 274.3) but 49% of the cohort received a diagnosis
after more than 1 year (17). In another study, the median time
for establishing a diagnosis was 1.5 years (range <1 week to 12
years) but this was calculated from the time of the first doctors’
appointment rather than onset of symptoms (12). Compared to
these historical studies, our results suggest fewer patients had
such long delays from symptom onset to diagnosis.
Delays in diagnosis can occur at each stage of the patient
journey and may be due to both patient- and healthcare-related
causes. The longest delay we observed occurred in stage 1
(Figure 1B). More delay in this stage translated into a prolonged
time to the final diagnosis. Our results show that only a quarter
(26.7%) of all patients did not delay their initial appointment
with their primary care physician. These findings are similar
to results from a patient survey conducted in 2015 (9). A
more recent survey amongst IPF patients reported a median
delay of 0.1 years for this stage (5). From our survey, those
who delayed their appointment reported they had not been
concerned about their symptoms. This highlights the need to
raise awareness of pulmonary fibrosis amongst the general public,
so that individuals seek medical assistance earlier.
The time taken by people being treated in primary care (stage
2) varies. In our survey, almost 40% of patients were referred to
a hospital specialist after their first primary care appointment,
which is greater than that observed in a study conducted in the
USA in 2015 (27.8%) (9). However, Hoyer et al. found that 80% of
patients in Denmark (between 2016 and 2019) were referred after
1 or 2 visits to their general practitioner (5). These observations
may reflect differences in healthcare systems or in awareness of
pulmonary fibrosis between countries.
Of all respondents, 15.3% were referred after 4 or more
appointments. Several factors may contribute to delays in
primary care. Firstly, initial symptoms in the early stage of
the disease can be non-specific and not yet known to be life
threatening. In support of this, 42% of IPF patients had a
normal lung function when initially assessed in primary care (18).
Secondly, primary care physicians may suspect the symptoms to
be due to more common respiratory diseases (such as asthma,
pneumonia, bronchitis, allergies, and COPD [9]) and decide
on a period of observation (20). Such misdiagnosis occurs in
up to 41% of patients (5) and can prolong time to establish
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an ILD diagnosis (9, 10). Thirdly, primary care physicians may
lack knowledge about pulmonary fibrosis. A study in Finland
found almost half of referral letters lack key information related
to possible ILD diagnosis (18). An e-learning for General
Practitioners has recently been launched by the Royal College
of General Practitioners in the United Kingdom and patient
organisation APF to increase knowledge about symptoms and
treatment of pulmonary fibrosis (21). In other countries, similar
initiatives are evolving.
Stage 3 is the time between being referred and the patient’s
actual hospital appointment. Based on our data, 76.9% were
assessed by a pulmonologist within 3 months, compared to 91%
reported from a Finnish cohort (18). In this Finnish study only
referral letters to tertiary care centres were evaluated, which may
explain the higher percentage. However, in the United Kingdom
and Ireland the time to secondary care respiratory clinic visit
[47 days (25–84)] was significantly less than the time to an ILD
specialist clinic visit [290 days (133–773)] (16). Given differences
in the structure and complexities of healthcare systems, it
is difficult to compare data from different countries. To our
knowledge, there are no published data as to why delays in stage
3 occur. It may reflect waiting times or patients postponing a
hospital clinic appointment.
Delays occurring from the first hospital appointment to final
diagnosis (stage 4) can be partly explained by the number of
diagnostic tests, access to them (22) and challenges in confirming
a specific diagnosis accurately. Patients in our survey underwent
on average 4.5 tests per person. The most common were
spirometry, blood tests, and radiological chest imaging, similar
to those reported by others (9, 14). The proportion of reported
lung biopsies was surprisingly high in our cohort (41.9–67.9%),
whichmay reflect variation in healthcare practises, as biopsy rates
differ between countries [16.1–1.2% (2013–2019) in England
(23), 34.1% in Germany (2012–2014) (24), 20.1% in Italy (2015–
2017) (25)].
Several parameters may predict potential delays, as they are
associated with an increased time to diagnosis. In our cohort
patients with a final diagnosis of IPF experience shorter delays
and undergo less invasive diagnostic testing than patients with
other diagnoses. These differences may be due to IPF patients
presenting with more severe symptoms initially, availability of
the IPF international diagnostic guidelines, or availability of
tests (22, 26). We can only speculate on this as we did not
collect data on disease severity nor have powered for separate
subgroup analyses. Another parameter that may influence time
to diagnosis are the specific presenting symptoms.When patients
present with dyspnoea, the median time to confirm an ILD
diagnosis was 307 days, which increased for symptoms as cough
and fatigue, to 563 and 639 days, respectively (15). Similarly,
Pritchard et al. found an association between dyspnoea and a
shorter time to hospital referral, which was not observed for
lung crackles or chronic cough (8). Other factors that may
contribute to a delayed diagnosis include presence of specific
comorbidities, male sex, increased body mass index, older age,
previous inhalation therapy use, preserved diffusing capacity and
better St. George’s Respiratory Questionnaire scores (5, 7, 16, 17).
Lastly, abnormal chest imaging is one of the main reasons to
initiate a hospital referral from primary care (8, 18) and naming
ILD on the thoracic CT radiologic report doubled the likelihood
of a referral to a pulmonologist within 6months (8). Interestingly,
performing lung function tests in primary care, which indicated
the possibility of ILD did not significantly influence time to CT
scan or hospital referral (8).
Patients’ Experiences
The pulmonary fibrosis journey to diagnosis generally involves
extensive, repetitive, and sometimes invasive testing. Most
patients in the survey reported that this causes a considerable
burden, which can impact on emotional health, finances, and
personal and professional life (9). Shortening the diagnostic
journey and assessment at an ILD expert centre results in higher
patient satisfaction (12). In addition, our survey highlighted
the need to better inform patients during their diagnostic
journey, to provide information on how to live with pulmonary
fibrosis and advice on lifestyle changes at diagnosis. After
diagnosis, providing information on perspectives, and options
and discussions concerning symptom management should also
be a priority as identified by our respondents. These observations
are similar to those reported from surveys and in-depth patient
interviews (27, 28). In one paper, authors highlighted that
patients need time to come to terms with their diagnosis
and that repeated provision of information was essential to
fully understand the consequences and implications of their
disease (11). However, a survey of ILD professionals in Europe
showed that although two-thirds of specialist centres offered
patient education only a few patients attended these existing
programmes (10). Furthermore, only 6% of patients from our
survey were informed about support groups, despite the value
of peer support to patients and carers reported not only by
our respondents but also from a previous patient survey (12).
However, scientific evidence for the benefits of peer support
is scarce (29). Regarding caregivers’ needs, several patients in
our survey highlighted the need to provide them with more
information on the patient’s experience and practical help
on how best to support them (30). Finally, providing details
of websites which offer reliable and accurate information is
important as many websites contain incorrect or out-dated
information (31).
Limitations
In this study, we used a variety of survey methods, which
resulted in a good understanding of patients’ perceptions
and experiences. Nevertheless, using patient reported data is
also a weakness of this study. A general limitation of open-
ended questions is the variety of responses, which could not
be included in the quantitative analysis. Limitations also
include patient recall, non-response, and misinformation
bias. These factors could have influenced the lung biopsies
reported in our cohort, as patients may not differentiate
between procedures such as endobronchial biopsies,
surgical biopsies, or only bronchoscopy. As the responses
were anonymous, we could not confirm information from
medical records.
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TABLE 2 | Strategies for improving the diagnostic pathway of pulmonary fibrosis patients.








Increase awareness of PF
symptoms amongst primary
care physicians and nurses.
Inform patients and policy
makers on the need for
urgency in hospital referral.














Develop criteria for referral






specialist and ILD experts.




support, helplines and peer




physician and ILD specialist.














PF to the general
population.
Cost-effectiveness of
performing chest CT scan in
primary care or at
community facilities.
Comparing waiting times and diagnostic pathway of PF
to other uncommon diseases or disorders with poor
prognosis [e.g., cancer (39)]
. Assess caregivers’ needs
on counselling and support.
Content is based on survey outcomes, available literature, and authors’ opinions. CT, computed tomography; DLCO, diffusing capacity for carbon monoxide; ILD, interstitial lung disease;
IPF, idiopathic pulmonary fibrosis; MDD, multidisciplinary discussion; PF, pulmonary fibrosis.
Several factors prevent generalisation of these results
to the overall population of patients with pulmonary
fibrosis. We used a non-random sample of self-selecting
pulmonary fibrosis patients invited via patient associations
without a pre-defined number of invited patients, target, or
countries. Most organisations have, until recently, focused
on supporting and representing IPF patients, which likely
accounts for the high number of IPF participants in this
survey. Furthermore, patient characteristics, such as gender,
age, comorbidities, and stage and/or severity of disease were
not collected.
Although there are European guidelines for the diagnostic
pathway of IPF and other ILDs, differences exist between
countries (10). This may be related to the organisation of
healthcare and options for primary care physicians to refer
for CT scans or to ILD expertise centres. In our survey,
we did not take these differences into account nor collect
information on whether a CT chest scan was performed in
primary care.
Recommendations Clinical Practice
There is an urgent need to improve the diagnostic journey
and recommendations on how to achieve this have been
raised in several papers (10, 12, 13). Our findings on
patient satisfaction and diagnostic delay endorse this and
encourage further improvement. Rapid diagnosis is becoming
increasingly important because several treatments are currently
available to slow disease progression, improve quality of
life, and may extend life expectancy (32–34). Although
there are guidelines and other guidance documents on
features, diagnosis, and management of ILD (26, 35–37)
many patients have a diagnosis that is not confirmed by a
multidisciplinary discussion and do not receive treatment
(38). Additionally, geographical differences that may influence
time to diagnosis and access to treatment still exists between
countries (10).
In Table 2, we provide concrete strategies for each stage
of the diagnostic journey to improve the standard clinical
practise and patient satisfaction in order to promote a more
rapid pathway for patients with pulmonary fibrosis throughout
Europe. These strategies are based upon our survey outcomes,
available literature, and expert authors’ opinions. Awareness and
education in general public, patients, and healthcare workers
is a major topic in this field, as well as for other rare lung
diseases (40).
CONCLUSION
From the onset of symptoms to diagnosis of pulmonary
fibrosis, the patient journey involves delays at each stage of
the diagnostic pathway. Most of these delays are avoidable.
Based upon our findings, there is a particular need to raise
awareness of pulmonary fibrosis in the general population.
Additionally, patients’ experiences highlight the need for
understandable information concerning the diagnostic tests
performed, differential diagnosis, final diagnosis, and treatments
as well as peer support groups. Improving several aspects
of the diagnostic pathway for pulmonary fibrosis is therefore
warranted to minimise delays and improve patient satisfaction
throughout Europe.
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